Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Contributions of the ADNI Biostatistics Core

Alzheimer s & Dementia(2024)10.1002/alz.14159Source: DataRank Database

Contributions of the ADNI Biostatistics Core is a dataset published in Alzheimer s & Dementia (2024). On theSindex it has a DataRank of 0.406, placing it in the top 45.3% of the data-sharing corpus. It has been cited 6 times, with 5 citing works in its 1-hop citation network.

Top 45%percentile

0.406DataRank

Ranks in the top 45% for downstream scientific impact

Data paper Open Access6 citations · 5 citing works in its network

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (50 grants)Impact (FWCI 2.01)OA: hybridTopics (42)IDs (PubMed, PMC, OpenAlex)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (1/3)

Dataset classification

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 72%Citation Network 28%

Base Score Contribution

0.292

From this paper's citation signal

Citation Network Contribution

0.114

From 3 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 5 citers.

Longitudinal Analysis of Amyloid PET and Brain MRI for Predicting Conversion from Mild Cognitive Impairment to Alzheimer’s Disease: Findings from the ADNI Cohort
Tomography20255 citations32 referencesContributes 0.056
Gender-based Alzheimer's detection using ResNet-50 and binary dragonfly algorithm on neuroimaging
Frontiers in Artificial Intelligence20256 citations40 referencesContributes 0.049
18F-FDG-PET and Multimodal Biomarker Integration: A Powerful Tool for Alzheimer’s Disease Diagnosis
Nuclear Medicine and Molecular Imaging20256 citations65 referencesContributes 0.030
Environmental Factors Drive Neurodegenerative Diseases Through Glutamate Excitotoxicity: A Convergent Mechanistic Pathway
Neuroscience Bulletin20260 citations197 referencesContributes 0.000
Contributions of the Alzheimer's Disease Neuroimaging Initiative to advancing AD research: a targeted review of recent publications
Alzheimer s & Dementia20260 citations184 referencesContributes 0.000

Authors (5)

Naomi Saito ORCID,Michael Donohue ORCID,Danielle Harvey ORCID,for the Alzheimer's Disease Neuroimaging Initiative,Laurel Beckett ORCID

Live enrichment

PubMed:39140601 PMC:PMC11485306 OpenAlex:https://openalex.org/W4401579948

National Institutes of Health

Grant: U19 AG024904

NIA NIH HHS

Grant: P30 AG072972

Canadian Institutes of Health Research

Grant: unidentified

unidentified

National Institutes of Health

Grant: 3U19AG024904-18S3

Alzheimer's Disease Neuroimaging Initiative (ADNI4)

Bristol-Myers Squibb Company

Elan Pharmaceuticals, Inc.

Alzheimer's Association

Alzheimer's Drug Discovery Foundation

Biogen

CereSpir, Inc.

Araclon Biotech

Canadian Institutes of Health Research

Eisai Inc.

EuroImmun

National Institute on Aging

Neurotrack Technologies

Transition Therapeutics

Alzheimer's Drug Discovery Foundation

CIHR

GE Healthcare

Northern California Institute for Research and Education

Fujirebio

Fujirebio US

Lumosity

Merck

Pfizer

Pfizer Inc.

Piramal Imaging

AbbVie

Alzheimer's Association

BioClinica

Bristol-Myers Squibb

F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.

Janssen Alzheimer Immunotherapy Research & Development, LLC

Johnson & Johnson Pharmaceutical Research &Development LLC

Lundbeck

Merck & Co., Inc.

NIBIB NIH HHS

NeuroRx Research

Novartis Pharmaceuticals Corporation

BioClinica, Inc.

Cogstate

Eli Lilly and Company

Foundation for the National Institutes of Health

Servier

Takeda Pharmaceutical Company

H. Lundbeck A/S

IXICO Ltd.

Meso Scale Diagnostics, LLC

National Institute of Biomedical Imaging and Bioengineering

FWCI

2.01

Citation Percentile

0.9%

Citation Trend

2024

2025

2026

hybridLicense: cc-by-nc-nd

journalhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/alz.14159

publisherhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/alz.14159

publisherhttps://alz-journals.onlinelibrary.wiley.com/doi/pdf/10.1002/alz.14159

journalhttps://doi.org/10.1002/alz.14159

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39140601

Fields of Study

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsHealth, Environment, Cognitive Aging0301 basic medicine03 medical and health sciences0302 clinical medicine

MeSH Terms

Alzheimer DiseaseHumansLongitudinal StudiesMaleResearch DesignBiomarkersDatabases, FactualBiostatisticsNeuroimaging

Keywords

Alzheimer's Disease Neuroimaging InitiativeBiostatisticsNeuroimagingBiomarkerComputer scienceClinical trialDementiaImaging biomarkerData scienceStandardizationMedicineDiseaseEpidemiologyPsychiatryPathologyClinical Trial DesignBiomarker ValidationData StandardizationBiomarker ProgressionMaleDatabases, FactualAlzheimer DiseaseResearch DesignHumansReview ArticleLongitudinal StudiesBiomarkers